STOCK TITAN

Vaxxinity Inc - VAXX STOCK NEWS

Welcome to our dedicated news page for Vaxxinity (Ticker: VAXX), a resource for investors and traders seeking the latest updates and insights on Vaxxinity.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vaxxinity's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vaxxinity's position in the market.

Rhea-AI Summary
Vaxxinity, Inc. (Nasdaq: VAXX) to present clinical data on its UB-312 program in Parkinson's disease at the AAN 2024 Annual Meeting. The presentation will focus on evidence of target engagement in a Phase 1 clinical trial, led by Dr. Jean-Cosme Dodart, CSO of Vaxxinity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.14%
Tags
conferences clinical trial
-
Rhea-AI Summary
Vaxxinity, Inc. (Nasdaq: VAXX) reports financial results for Q4 and full year 2023, focusing on neurodegeneration programs and vaccine candidates. Positive developments include promising biomarker data for UB-312 in Parkinson's disease, encouraging results from VXX-401 in hypercholesterolemia, and progress with UB-612 COVID-19 booster. CEO Mei Mei Hu highlights the company's advancements and upcoming milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.14%
Tags
earnings
-
Rhea-AI Summary
Vaxxinity, Inc. announces positive clinical data for UB-312 program in Parkinson's disease, showing reduction of pathological alpha-synuclein in cerebrospinal fluid. The first active immunotherapy candidate to target aggregated forms of aSyn, UB-312 demonstrated promising results in a Phase 1 clinical trial, funded by The Michael J. Fox Foundation. Patients treated with UB-312 exhibited a 20% decrease in aggregated aSyn compared to the placebo group, with potential improvements in daily living activities. Vaxxinity aims to revolutionize Parkinson's treatment with disease-modifying therapies, offering hope for better outcomes in the near future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.58%
Tags
clinical trial
Rhea-AI Summary
Vaxxinity, Inc. announces promising preclinical data for VXX-401, a potential treatment for hypercholesterolemia and atherosclerotic cardiovascular disease. The synthetic peptide vaccine shows significant LDL-C reduction in non-human primate studies, with a Phase 1 trial ongoing and topline results expected in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.97%
Tags
clinical trial
-
Rhea-AI Summary
Vaxxinity, Inc. (Nasdaq: VAXX) announces the presentation of clinical data from its UB-312 program in Parkinson’s disease and preclinical data from its anti-tau program in Alzheimer’s disease at the AD/PD 2024 conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.59%
Tags
conferences
-
Rhea-AI Summary
Vaxxinity, Inc. (Nasdaq: VAXX) announced a research collaboration with the University of Florida’s Center for Translational Research in Neurodegenerative Disease to develop vaccines for neurodegenerative diseases. The collaboration aims to further the development of Vaxxinity’s active immunotherapies to prevent and mitigate neurodegenerative diseases, such as Alzheimer's and Parkinson's. The project will complement preclinical work conducted at Vaxxinity, which has already shown immunogenicity, target engagement, and efficacy in animal models of multiple neurodegenerative diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.71%
Tags
none
Rhea-AI Summary
Vaxxinity, Inc. (Nasdaq: VAXX) has announced a collaboration with the University of Central Florida (UCF) to advance space medicine research funded by a grant from the State of Florida. The research aims to develop active immunotherapies to prevent and mitigate muscle and bone wasting related to long-term spaceflight and age-related diseases. Vaxxinity's platform is designed to harness and selectively activate the immune system by overcoming immune tolerance, stimulating the production of antibodies against endogenous targets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.91%
Tags
none
-
Rhea-AI Summary
Vaxxinity, Inc. (Nasdaq: VAXX) CEO to Present Company Update at J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.7%
Tags
conferences
-
Rhea-AI Summary
Vaxxinity, Inc. (Nasdaq: VAXX) announced its participation in three upcoming medical and investor conferences in November. The company's scientists and executives will present their findings, including the novel peptide/protein subunit COVID-19 vaccine booster UB-612, which stimulated broadly neutralizing and Fc-mediated effector antibodies in a Phase 3 clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.18%
Tags
conferences
Rhea-AI Summary
Vaxxinity, Inc. (Nasdaq: VAXX) reported Q3 2023 financial results and a corporate update. The company made progress with clinical programs for Parkinson's and Alzheimer's diseases, and hypercholesterolemia. They also announced a potential COVID-19 booster and additions to the executive team. Financially, Vaxxinity had $42.5 million in liquid assets as of September 30, 2023, and a net loss of $13.1 million for the quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.46%
Tags
earnings
Vaxxinity Inc

Nasdaq:VAXX

VAXX Rankings

VAXX Stock Data

90.94M
55.31M
50.93%
12.3%
3.04%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Merritt Island

About VAXX

vaccines against chronic diseases